Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12991853 | 0.87 | BDKRB1 (0.57) | LMNAHTTCNR2ALDH1A1HPGD | |
| SCHEMBL12426304 | 0.84 | CNR2 (0.60) | LMNAHTTCNR2ALDH1A1HPGD | |
| SCHEMBL24002931 | 0.83 | HTT (0.58) | HTTCNR2ALDH1A1HPGDRAB9A | |
| SCHEMBL30305085 | 0.83 | HTT (0.58) | HTTCNR2ALDH1A1HPGDRAB9A | |
| SCHEMBL19116336 | 0.83 | CNR2 (0.53) | LMNAHTTCNR2ALDH1A1HPGD | |
| SCHEMBL22560798 | 0.83 | CNR2 (0.53) | LMNAHTTCNR2ALDH1A1HPGD | |
| SCHEMBL1184896 | 0.83 | CNR2 (0.53) | HTTCNR2ALDH1A1HPGDRAB9A | |
| SCHEMBL1169382 | 0.81 | ALDH1A1 (0.54) | LMNAHTTCNR2ALDH1A1HPGD | |
| SCHEMBL1168814 | 0.79 | SMN1; SMN2 (0.52) | HTTCNR2ALDH1A1HPGDRAB9A | |
| SCHEMBL20546008 | 0.78 | KDM4E (0.58) | LMNAHTTCNR2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143368-A1 | Use of Cinnamoyl Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090143368-A1 | Use of Cinnamoyl Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1857104-A1 | USE OF CINNAMOYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2007-11-21 | — | — | EP | disclosed |
| EP-1857104-A1 | USE OF CINNAMOYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143368-A1 | Use of Cinnamoyl Compound | COL2A1, COL1A1, SMAD2 | LMNA 1153/4885HTT 4044/4885CNR2 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.